Vycor Medical (VYCO) 10-Q 10 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 10, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-34932
Entity Registrant Name	VYCOR MEDICAL, INC.
Entity Central Index Key	0001424768
Entity Tax Identification Number	20-3369218
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	951 Broken Sound Parkway
Entity Address, Address Line Two	Suite 320
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33487
City Area Code	561
Local Phone Number	558-2020
Title of 12(b) Security	Common Stock
Trading Symbol	VYCO
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		31,455,744

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current Assets
Cash	$ 80,567	$ 90,941
Trade accounts receivable	161,783	126,096
Inventory	204,466	207,521
Prepaid expenses and other current assets	65,886	62,473
Current assets of discontinued operations	182	380
Total Current Assets	512,884	487,411
Fixed assets, net	346,042	362,393
Intangible and Other assets:
Security deposits	6,000	6,000
Operating lease - right of use assets	68,053	79,560
Total Intangible and Other assets	74,053	85,560
TOTAL ASSETS	932,979	935,364
Current Liabilities
Accounts payable	182,573	227,720
Accrued interest: Other	390,599	380,479
Accrued interest: Related party	114,356	106,444
Accrued liabilities - Other	123,937	126,959
Accrued liabilities - Related Party	1,784,035	1,621,850
Notes payable: Other	309,057	319,329
Notes payable: Related Party	400,873	320,873
Current operating lease liabilities	47,518	46,915
Current liabilities of discontinued operations	(616)	(572)
Total Current Liabilities	3,352,332	3,149,997
Loan Payable - SBA EIDL	148,681	150,000
Operating lease liability - Long term	18,379	30,580
Total Long-term Liabilities	167,060	180,580
Total Liabilities	3,519,392	3,330,577
STOCKHOLDERS’ DEFICIENCY
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 270,307 and 270,307 issued and outstanding as at March 31, 2022 and December 31, 2021 respectively	27	27
Common Stock, $0.0001 par value, 55,000,000 shares authorized at March 31, 2022 and December 31, 2021, 31,457,415 and 30,921,701 shares issued and 31,354,081 and 30,818,367 outstanding at March 31, 2022 and December 31, 2021 respectively	3,146	3,092
Additional Paid-in Capital	29,217,651	29,172,169
Treasury Stock (103,334 shares of Common Stock as at March 31, 2022 and December 31, 2021 respectively, at cost)	(1,033)	(1,033)
Accumulated Deficit	(31,933,879)	(31,697,142)
Accumulated Other Comprehensive Income	127,675	127,674
Total Stockholders’ Deficiency	(2,586,413)	(2,395,213)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY	$ 932,979	$ 935,364

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	270,307	270,307
Preferred stock, shares outstanding	270,307	270,307
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	55,000,000	55,000,000
Common stock, shares issued	31,457,415	30,921,701
Common stock, shares outstanding	31,354,081	30,818,367
Treasury stock, shares	103,334	103,334

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue	$ 313,833	$ 295,749
Cost of Goods Sold	33,409	28,477
Gross Profit	280,424	267,272
Operating Expenses:
Research and development		2,700
Depreciation and amortization	14,649	13,945
Selling, general and administrative	318,674	457,476
Total Operating expenses	333,323	474,121
Operating loss	(52,899)	(206,849)
Other Income (Expense)
Interest expense: Related Party	(7,912)	(7,665)
Interest expense: Other	(12,314)	(16,118)
Loss on foreign currency exchange	(672)	(115)
Total Other Income (Expense)	(20,898)	(23,898)
Loss Before Credit for Income Taxes	(73,797)	(230,747)
Credit for income taxes
Net Loss from continuing operations	(73,797)	(230,747)
Loss from discontinued operations	(755)	(12,172)
Net loss	(74,552)	(242,919)
Preferred stock dividends	(162,185)	(162,185)
Net Loss Available to Common Stockholders	(236,737)	(405,104)
Other Comprehensive Income
Foreign Currency Translation Adjustment	1	7
Comprehensive Loss	$ (74,551)	$ (242,912)
Net Loss Per Share – basic and diluted
Loss from continuing operations	$ (0.01)	$ (0.01)
Loss from discontinued operations	0	0
Net Loss available to common shareholders	$ (0.01)	$ (0.01)
Weighted Average Number of Shares Outstanding – Basic and Diluted	30,824,320	27,831,540

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Balance	$ (2,395,213)	$ (1,981,316)
Issuance of stock for board and consulting fees	45,536	101,430
Issuance of stock related to deferred compensation of directors
Directors deferred compensation granted		21,000
Accumulated Comprehensive Loss	1	7
Net loss	(236,737)	(405,104)
Balance	(2,586,413)	(2,263,983)
Common Stock [Member]
Balance	$ 3,093	$ 2,753
Balance, shares	30,921,701	27,534,740
Issuance of stock for board and consulting fees	$ 54	$ 54
Issuance of stock for board and consulting fees, shares	535,714	535,714
Issuance of stock related to deferred compensation of directors		$ 47
Issuance of stock related to deferred compensation of directors, shares		466,794
Balance	$ 3,147	$ 2,854
Balance, shares	31,457,415	28,537,248
Preferred Stock [Member] | Preferred C [Member]
Balance	$ 0	$ 0
Balance, shares	1	1
Directors deferred compensation granted
Accumulated Comprehensive Loss
Balance	$ 0	$ 0
Balance, shares	1	1
Preferred Stock [Member] | Preferred D [Member]
Balance	$ 27	$ 27
Balance, shares	270,306	270,306
Directors deferred compensation granted
Accumulated Comprehensive Loss
Balance	$ 27	$ 27
Balance, shares	270,306	270,306
Treasury Stock [Member]
Balance	$ (1,033)	$ (1,033)
Balance, shares	(103,334)	(103,334)
Directors deferred compensation granted
Accumulated Comprehensive Loss
Balance	$ (1,033)	$ (1,033)
Balance, shares	(103,334)	(103,334)
Additional Paid-in Capital [Member]
Balance	$ 29,172,169	$ 28,826,378
Issuance of stock for board and consulting fees	45,482	101,376
Issuance of stock related to deferred compensation of directors		(47)
Directors deferred compensation granted		21,000
Balance	29,217,651	28,948,707
Retained Earnings [Member]
Balance	(31,697,142)	(30,937,110)
Directors deferred compensation granted
Accumulated Comprehensive Loss
Net loss	(236,737)	(405,104)
Balance	(31,933,879)	(31,342,214)
AOCI Attributable to Parent [Member]
Balance	127,674	127,669
Accumulated Comprehensive Loss	1	7
Balance	$ 127,675	$ 127,676

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (74,552)	$ (242,919)
Adjustments to reconcile net loss to cash used in operating activities:
Amortization of intangible assets		2,994
Depreciation of fixed assets	15,563	11,162
Inventory provision	5,960	3,090
Stock based compensation	50,568	122,430
Changes in assets and liabilities:
Accounts receivable	(35,686)	15,382
Inventory	(2,117)	(21,628)
Prepaid expenses	(8,536)	16,600
Accrued interest - Related Party	7,912	7,665
Accrued interest - Other	10,120	16,118
Accounts payable	(45,147)	36,038
Accrued liabilities - Other	(3,021)	4,391
Changes in discontinued operations, net	156	(5,483)
Cash used in operating activities	(78,780)	(34,160)
Cash flows from investing activities:
Purchase of fixed assets		(23,935)
Cash used in investing activities		(23,935)
Cash flows from financing activities:
Proceeds from Notes Payable - Related Party	80,000	10,000
Proceeds from Paycheck Protection Program and EIDL		58,600
Proceeds net of repayments Notes Payable - Other	(11,591)	(17,470)
Cash provided by financing activities	68,409	51,130
Effect of exchange rate changes on cash	(3)	7
Net increase (decrease) in cash	(10,376)	(6,958)
Cash at beginning of period	90,941	46,002
Cash at end of period	80,567	39,044
Supplemental Disclosures of Cash Flow information:
Cash paid for interest	2,193	0
Cash paid for income tax	$ 0	$ 0

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	1. BASIS OF PRESENTATION The accompanying unaudited consolidated financial statements of Vycor Medical, Inc. (the “Company” or “Vycor”) have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in consolidated financial statements have been omitted pursuant to such rules and regulations. The consolidated balance sheet as of December 31, 2021 derives from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These unaudited consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The unaudited consolidated financial statements as of and for the three months ended March 31, 2022 and 2021, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition, results of operations and cash flows. The results of operations for the three months ended March 31, 2022 and 2021 are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Certain prior period amounts on the unaudited consolidated financial statements have been reclassified to conform to the current period presentation. Ability to continue as a Going Concern The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred losses since its inception, including a net loss of $ 236,737 540,184 2,299,264 The Company is executing on a plan to achieve a reduction in cash operating losses. Included within the working capital deficiency above is a term note for $ 300,000 388,733

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	2. SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The unaudited consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company account balances, transactions, and profits have been eliminated in consolidation. Following the decision in April 2020 to close the German office of NovaVision, the activities of NovaVision GmbH have been accounted for as discontinued operations. Recent Accounting Pronouncements From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented. Discontinued Operations In accordance with ASU No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the components of an entity meets the criteria in paragraph 205-20-45-1E to be classified as held for sale. When all of the criteria to be classified as held for sale are met, including management, having the authority to approve the action, commits to a plan to sell the entity, the major current assets, other assets, current liabilities, and noncurrent liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations (which we presented as operations to be disposed and operations disposed), less applicable income taxes (benefit), shall be reported as components of net income (loss) separate from the net income (loss) of continuing operations in accordance with ASC 205-20-45. Accounting for forgivable loan received under the Small Business Administration Paycheck Protection Program During the year ended December 31, 2020 the Company received a loan of $ 58,600 58,600 The Company accounted for the loans as a financial liability in accordance with FASB ASC 470 and accrued interest in accordance with the interest method under FASB ASC 835-30. For purposes of derecognition of the liability, FASB ASC 470-50-15-4 refers to guidance in FASB ASC 405-20. Based on this guidance, the proceeds of the loans were recorded as a liability until either (1) the loans are, in part or wholly, forgiven and the Company has been “legally released”, or (2) the Company pays off the loans. The Company has accordingly reduced the liability by the amount forgiven and recorded a gain on the extinguishment. Net Loss Per Share Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive. The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share: SCHEDULE OF COMMON STOCK NOT INCLUDED IN CALCULATION OF DILUTED NET LOSS PER SHARE March 31, 2022 March 31, 2021 Stock options outstanding - 660,000 Debentures convertible into common stock 3,279,676 3,051,106 Preferred shares convertible into common stock 1,272,052 1,272,052 Directors Deferred Compensation Plan - 1,142,442 Total 4,551,728 6,125,600

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	3 Months Ended
	Mar. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	3. DISCONTINUED OPERATIONS In April 2020, the board of Vycor took the decision to close the German operations of NovaVision, including the German office and NovaVision GmbH, and instead migrate to a licensed business model; in June 2020 Vycor announced that it would be entering into a license agreement and transition agreement (the “Agreements”) with HelferApp GmbH, a cognitive therapy specialist. Under the Agreements, HelferApp is licensed to provide NovaVision’s products and therapies in Germany, Austria and Switzerland to patients and professionals; and has assumed responsibility for the current patients of NovaVision in the territory. The NovaVision German office was closed effective June 30, 2020. The Company will continue to fund the remaining expenses of the German operations, which are non-material, until such a time as NovaVision GmbH will be formally wound up. Reconciliation of the major line items from discontinued operations that are presented in the unaudited consolidated balance sheets and unaudited consolidated statements of comprehensive loss are as follows: Major line items constituting assets and liabilities in the unaudited consolidated balance sheets SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS March 31, 2022 December 31, ASSETS Current Assets Cash $ 182 $ 380 Total Current Assets 182 380 TOTAL ASSETS $ 182 $ 380 LIABILITIES Current Liabilities Accounts payable $ 4 $ 4 Accrued liabilities - Other - - Other current liabilities (620 ) (576 ) Total Current Liabilities $ (616 ) $ (572 ) Major line items constituting loss from discontinued operations 2022 2021 For the three months ended March 31, 2022 2021 Revenue $ - $ - Cost of Goods Sold - - Gross Profit - - Operating Expenses: Selling, general and administrative 751 11,569 Total Operating expenses 751 11,569 Operating Loss (751 ) (11,569 ) Other Income (Expense) Loss on foreign currency exchange (4 ) (603 ) Total Other Income (Expense) (4 ) (603 ) Loss Before Credit for Income Taxes (755 ) (12,172 ) Credit for income taxes - - Loss from discontinued operations, net of tax $ (755 ) $ (12,172 )

NOTES PAYABLE

NOTES PAYABLE	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
NOTES PAYABLE	4. NOTES PAYABLE Related Parties Notes Payable Related Party Notes Payable consists of: SUMMARY OF NOTES PAYABLE March 31, 2022 December 31, 2021 On June 25, 2018 the Company issued promissory notes to Peter Zachariou for $ 30,000 10 $ 30,000 $ 30,000 Between March 26, 2018 and March 25, 2022 the Company issued twelve promissory notes to Fountainhead Capital Management Limited for $ 370,873 10 The Notes will be due between July 2022 and May 2023 or on demand by the Payee. 370,873 290,873 Total Related Party Notes Payable $ 400,873 $ 320,873 Other Notes Payable Other Notes Payable consists of: March 31, 2022 December 31, 2021 On March 25, 2011 the Company issued a term note for $ 300,000 16 June 25, 2011 March 31, 2023 $ 300,000 $ 300,000 Current portion of Long-Term Notes payable, see below 1,319 - Insurance policy finance agreements. 7,738 19,329 Total Notes Payable: $ 309,057 $ 319,329 Long-Term Notes Payable consists of: March 31, 2022 December 31, 2021 On July 7, 2020, the Company was advised that the Small Business Administration (SBA) had approved a $ 150,000 30 3.75 731 $ 148,681 $ 150,000 Total Long-Term Notes Payable: $ 148,681 $ 150,000 In January 2018 the Company entered into an amendment agreement (the “Amendment”) with EuroAmerican Investments (“EuroAmerican”) regarding its $ 300,000 0.21 3,279,676 March 31, 2023 The Company routinely finances all their insurance policies through a third party finance company which requires a down payment and subsequent monthly payments, the time periods vary from 10 months to 12 equal monthly payments.

LEASE

LEASE	3 Months Ended
	Mar. 31, 2022
Lease
LEASE	5. LEASE The Company recognized the following related to a lease in its unaudited consolidated balance sheet at March 31, 2022 and December 31, 2021: SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES March 31, 2022 December 31, 2021 Operating Lease ROU Assets $ 68,053 $ 79,560 Operating Lease ROU Assets $ 68,053 $ 79,560 Operating Lease Liabilities Current portion 47,518 46,915 Long-term portion $ 18,379 $ 30,580 Operating Lease Liabilities $ 65,897 $ 77,495

SEGMENT REPORTING, GEOGRAPHICAL

SEGMENT REPORTING, GEOGRAPHICAL INFORMATION	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
SEGMENT REPORTING, GEOGRAPHICAL INFORMATION	6. SEGMENT REPORTING, GEOGRAPHICAL INFORMATION (a) Business segments The Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss and which includes Sight Science. Discontinued operations were part of NovaVision and revenues and assets were in Europe; see Note 3. Set out below are the revenues, gross profits and total assets for each segment: SCHEDULE OF BUSINESS SEGMENTS INFORMATION 2022 2021 Three Months Ended 2022 2021 Revenue: Vycor Medical $ 287,356 $ 262,714 NovaVision $ 26,477 $ 33,035 Revenue $ 313,833 $ 295,749 Gross Profit Vycor Medical $ 256,337 $ 235,932 NovaVision $ 24,087 $ 31,340 Gross Profit $ 280,424 $ 267,272 March 31, December 31, 2022 2021 Total Assets: Vycor Medical $ 910,098 $ 901,930 NovaVision 22,699 33,054 Discontinued operations 182 380 Total Assets $ 932,979 $ 935,364 (b) Geographic information The Company operates in two geographic segments, the United States and Europe. Discontinued operations were part of NovaVision and revenues and assets were in Europe; see Note 3. Set out below are the revenues, gross profits and total assets for each segment. SUMMARY OF GEOGRAPHIC INFORMATION 2022 2021 Three Months Ended 2022 2021 Revenue: United States $ 310,605 $ 288,780 Europe $ 3,228 $ 6,969 Revenue $ 313,833 $ 295,749 Gross Profit United States $ 277,212 $ 260,371 Europe $ 3,212 $ 6,901 Gross Profit $ 280,424 $ 267,272 March 31, December 31, 2022 2021 Total Assets: United States $ 926,757 $ 928,761 Europe 6,040 6,223 Discontinued operations 182 380 Total Assets $ 932,979 $ 935,364

EQUITY

EQUITY	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
EQUITY	7. EQUITY Equity Transactions During January to March 2022 and 2021, the Company granted 0 99,999 0 21,000 th In January 2021 the Company issued 466,794 On April 1, 2021 the Company issued 101,663 During January to March 2022 and 2021, under the terms of the Consulting Agreement referred to in note 10, the Company issued 535,714 45,536 101,430 Stock Options The details of the outstanding stock options are as follows: SCHEDULE OF STOCK OPTIONS Number of shares Weighted average exercise price Outstanding at December 31, 2020 680,000 $ 0.28 Granted - - Exercised - - Cancelled or expired (680,000 ) 0.28 Outstanding at December 31, 2021 - $ - Granted - - Exercised - - Cancelled or expired - - Outstanding at March 31, 2022 - $ - As of March 31, 2022, the weighted-average remaining contractual life of outstanding options is 0

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	8. STOCK-BASED COMPENSATION The Company from time to time issues common stock, stock options or common stock warrants to acquire services or goods from non-employees. Common stock, stock options and common stock warrants issued to other than employees or directors are recorded on the basis of their fair value, which is measured as of the “measurement date” using an option pricing model, or their contractual value if different in the case of common stock. The “measurement date” for options and warrants related to contracts that have substantial disincentives to non-performance is the date of the contract, and for all other contracts is the vesting date. Expense related to the options and warrants is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. Non-Employee Stock Compensation Aggregate stock-based compensation for stock granted to non-employees for each of the three months ended March 31, 2022 and 2021 was $ 50,568 122,430 0

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	9. COMMITMENTS AND CONTINGENCIES Lease The Company leases office space located at 951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487 from WPT Land 2 L.P., for a gross rent of approximately $ 4,000 1,500 The lease terminated September 30, 2020 and was extended for a further three years to August 31, 2023. 1,650 1,815 20,604 19,477 Potential German tax liability In June 2012 the Company’s NovaVision German subsidiary received a preliminary assessment for Magdeburg City trade tax of € 75,000 82,000 12,000 13,200 75,000 82,000 12,000 13,200

CONSULTING AND OTHER AGREEMENTS

CONSULTING AND OTHER AGREEMENTS	3 Months Ended
	Mar. 31, 2022
Consulting And Other Agreements
CONSULTING AND OTHER AGREEMENTS	10. CONSULTING AND OTHER AGREEMENTS The following agreements were entered into or remained in force during the period ended March 31, 2022: Consulting Agreement with Fountainhead In March 2017 and effective April 1, 2017, the Company amended the Fountainhead Consulting Agreement. Under the Amended Agreement, fees of $ 450,000 5,000 0.21 Effective January 1, 2021, the Company made a slight amendment to the Fountainhead Consulting Agreement (“the Amended Agreement”). Under the Amended Agreement, fees are payable to Fountainhead, with an option to receive $ 5,000 535,714 0.21 112,500 During the three months ended March 31, 2022 and March 31, 2021, under the terms of the Amended Agreement, Fountainhead received 535,714 45,536 101,430 Other Agreements On March 30, 2021, Vycor entered into a Consulting Agreement with Ricardo J. Komotar, M.D. (the “Agreement”) to provide certain specified services over the three-year term of the Agreement. Under the Agreement, Dr. Komotar will provide general scientific advisory consultancy services, and will also provide scientific advisory services based around certain specific pre-determined milestones. In consideration of the Consultant’s services, the Company agreed to deliver to the Consultant over the course of the three-year term, a total of 304,989 1,219,957 101,663

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	11. RELATED PARTY TRANSACTIONS Peter Zachariou and David Cantor, directors of the Company, are investment managers of Fountainhead which owned, at March 31, 2022, 61.5 69.7 0.16 25.7 During each of the three months ended March 31, 2022 and March 31, 2021, under the terms of the Consulting Agreement referred to in note 10, the Company issued 535,714 45,536 101,430 During each of the three months ended March 31, 2022 and 2021, the Company accrued an aggregate of $ 162,185 113,019 41,693 1,784,040 1,459,669 1,243,205 1,017,167 458,622 375,237 During the three months ended March 31, 2022 and 2021 the Company issued unsecured loan notes to Fountainhead for a total of $ 80,000 10,000 10 due on demand or by their one-year anniversary There were no

CONCENTRATION

CONCENTRATION	3 Months Ended
	Mar. 31, 2022
Risks and Uncertainties [Abstract]
CONCENTRATION	12. CONCENTRATION Vycor Medical sells its neurosurgical devices in the US primarily direct to hospitals, and internationally through distributors who in turn sell to hospitals. SCHEDULE OF CONCENTRATION Sales Concentration: Three Months Ended March 31, 2022 2021 Number of customers over 10% 0 0 Percentage of sales 0 % 0 % Accounts Receivable Concentration At March 31, At December 31, 2022 2021 Number of customers over 10% 0 1 Percentage of accounts receivable 0 % 11 % The Company has three sub-contract manufacturers from which it purchases, respectively, VBAS injection molded parts, completed and sterilized VBAS units, and VBAS extension arms. Purchases from these manufacturers vary from quarter to quarter, with no purchases in some quarters, however on an annual basis purchases from each manufacturer represent over 10

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	13. SUBSEQUENT EVENTS On April 1, 2022 the Company issued 101,663 The Company has evaluated the existence of events and transactions subsequent to the balance sheet date through the date the consolidated financial statements were issued and has determined that, other than that disclosed above, there were no significant subsequent events or transactions that would require recognition or disclosure in the financial statements.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The unaudited consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company account balances, transactions, and profits have been eliminated in consolidation. Following the decision in April 2020 to close the German office of NovaVision, the activities of NovaVision GmbH have been accounted for as discontinued operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.
Discontinued Operations	Discontinued Operations In accordance with ASU No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the components of an entity meets the criteria in paragraph 205-20-45-1E to be classified as held for sale. When all of the criteria to be classified as held for sale are met, including management, having the authority to approve the action, commits to a plan to sell the entity, the major current assets, other assets, current liabilities, and noncurrent liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations (which we presented as operations to be disposed and operations disposed), less applicable income taxes (benefit), shall be reported as components of net income (loss) separate from the net income (loss) of continuing operations in accordance with ASC 205-20-45.
Accounting for forgivable loan received under the Small Business Administration Paycheck Protection Program	Accounting for forgivable loan received under the Small Business Administration Paycheck Protection Program During the year ended December 31, 2020 the Company received a loan of $ 58,600 58,600 The Company accounted for the loans as a financial liability in accordance with FASB ASC 470 and accrued interest in accordance with the interest method under FASB ASC 835-30. For purposes of derecognition of the liability, FASB ASC 470-50-15-4 refers to guidance in FASB ASC 405-20. Based on this guidance, the proceeds of the loans were recorded as a liability until either (1) the loans are, in part or wholly, forgiven and the Company has been “legally released”, or (2) the Company pays off the loans. The Company has accordingly reduced the liability by the amount forgiven and recorded a gain on the extinguishment.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive. The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share: SCHEDULE OF COMMON STOCK NOT INCLUDED IN CALCULATION OF DILUTED NET LOSS PER SHARE March 31, 2022 March 31, 2021 Stock options outstanding - 660,000 Debentures convertible into common stock 3,279,676 3,051,106 Preferred shares convertible into common stock 1,272,052 1,272,052 Directors Deferred Compensation Plan - 1,142,442 Total 4,551,728 6,125,600

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
SCHEDULE OF COMMON STOCK NOT INCLUDED IN CALCULATION OF DILUTED NET LOSS PER SHARE	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share: SCHEDULE OF COMMON STOCK NOT INCLUDED IN CALCULATION OF DILUTED NET LOSS PER SHARE March 31, 2022 March 31, 2021 Stock options outstanding - 660,000 Debentures convertible into common stock 3,279,676 3,051,106 Preferred shares convertible into common stock 1,272,052 1,272,052 Directors Deferred Compensation Plan - 1,142,442 Total 4,551,728 6,125,600

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	3 Months Ended
	Mar. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS	SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS March 31, 2022 December 31, ASSETS Current Assets Cash $ 182 $ 380 Total Current Assets 182 380 TOTAL ASSETS $ 182 $ 380 LIABILITIES Current Liabilities Accounts payable $ 4 $ 4 Accrued liabilities - Other - - Other current liabilities (620 ) (576 ) Total Current Liabilities $ (616 ) $ (572 ) Major line items constituting loss from discontinued operations 2022 2021 For the three months ended March 31, 2022 2021 Revenue $ - $ - Cost of Goods Sold - - Gross Profit - - Operating Expenses: Selling, general and administrative 751 11,569 Total Operating expenses 751 11,569 Operating Loss (751 ) (11,569 ) Other Income (Expense) Loss on foreign currency exchange (4 ) (603 ) Total Other Income (Expense) (4 ) (603 ) Loss Before Credit for Income Taxes (755 ) (12,172 ) Credit for income taxes - - Loss from discontinued operations, net of tax $ (755 ) $ (12,172 )

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
SUMMARY OF NOTES PAYABLE	Related Party Notes Payable consists of: SUMMARY OF NOTES PAYABLE March 31, 2022 December 31, 2021 On June 25, 2018 the Company issued promissory notes to Peter Zachariou for $ 30,000 10 $ 30,000 $ 30,000 Between March 26, 2018 and March 25, 2022 the Company issued twelve promissory notes to Fountainhead Capital Management Limited for $ 370,873 10 The Notes will be due between July 2022 and May 2023 or on demand by the Payee. 370,873 290,873 Total Related Party Notes Payable $ 400,873 $ 320,873 Other Notes Payable Other Notes Payable consists of: March 31, 2022 December 31, 2021 On March 25, 2011 the Company issued a term note for $ 300,000 16 June 25, 2011 March 31, 2023 $ 300,000 $ 300,000 Current portion of Long-Term Notes payable, see below 1,319 - Insurance policy finance agreements. 7,738 19,329 Total Notes Payable: $ 309,057 $ 319,329 Long-Term Notes Payable consists of: March 31, 2022 December 31, 2021 On July 7, 2020, the Company was advised that the Small Business Administration (SBA) had approved a $ 150,000 30 3.75 731 $ 148,681 $ 150,000 Total Long-Term Notes Payable: $ 148,681 $ 150,000 In January 2018 the Company entered into an amendment agreement (the “Amendment”) with EuroAmerican Investments (“EuroAmerican”) regarding its $ 300,000 0.21 3,279,676 March 31, 2023 The Company routinely finances all their insurance policies through a third party finance company which requires a down payment and subsequent monthly payments, the time periods vary from 10 months to 12 equal monthly payments.

LEASE (Tables)

LEASE (Tables)	3 Months Ended
	Mar. 31, 2022
Lease
SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES	The Company recognized the following related to a lease in its unaudited consolidated balance sheet at March 31, 2022 and December 31, 2021: SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES March 31, 2022 December 31, 2021 Operating Lease ROU Assets $ 68,053 $ 79,560 Operating Lease ROU Assets $ 68,053 $ 79,560 Operating Lease Liabilities Current portion 47,518 46,915 Long-term portion $ 18,379 $ 30,580 Operating Lease Liabilities $ 65,897 $ 77,495

SEGMENT REPORTING, GEOGRAPHIC_2

SEGMENT REPORTING, GEOGRAPHICAL INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
SCHEDULE OF BUSINESS SEGMENTS INFORMATION	SCHEDULE OF BUSINESS SEGMENTS INFORMATION 2022 2021 Three Months Ended 2022 2021 Revenue: Vycor Medical $ 287,356 $ 262,714 NovaVision $ 26,477 $ 33,035 Revenue $ 313,833 $ 295,749 Gross Profit Vycor Medical $ 256,337 $ 235,932 NovaVision $ 24,087 $ 31,340 Gross Profit $ 280,424 $ 267,272 March 31, December 31, 2022 2021 Total Assets: Vycor Medical $ 910,098 $ 901,930 NovaVision 22,699 33,054 Discontinued operations 182 380 Total Assets $ 932,979 $ 935,364
SUMMARY OF GEOGRAPHIC INFORMATION	SUMMARY OF GEOGRAPHIC INFORMATION 2022 2021 Three Months Ended 2022 2021 Revenue: United States $ 310,605 $ 288,780 Europe $ 3,228 $ 6,969 Revenue $ 313,833 $ 295,749 Gross Profit United States $ 277,212 $ 260,371 Europe $ 3,212 $ 6,901 Gross Profit $ 280,424 $ 267,272 March 31, December 31, 2022 2021 Total Assets: United States $ 926,757 $ 928,761 Europe 6,040 6,223 Discontinued operations 182 380 Total Assets $ 932,979 $ 935,364

EQUITY (Tables)

EQUITY (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
SCHEDULE OF STOCK OPTIONS	SCHEDULE OF STOCK OPTIONS Number of shares Weighted average exercise price Outstanding at December 31, 2020 680,000 $ 0.28 Granted - - Exercised - - Cancelled or expired (680,000 ) 0.28 Outstanding at December 31, 2021 - $ - Granted - - Exercised - - Cancelled or expired - - Outstanding at March 31, 2022 - $ -

CONCENTRATION (Tables)

CONCENTRATION (Tables)	3 Months Ended
	Mar. 31, 2022
Risks and Uncertainties [Abstract]
SCHEDULE OF CONCENTRATION	SCHEDULE OF CONCENTRATION Sales Concentration: Three Months Ended March 31, 2022 2021 Number of customers over 10% 0 0 Percentage of sales 0 % 0 % Accounts Receivable Concentration At March 31, At December 31, 2022 2021 Number of customers over 10% 0 1 Percentage of accounts receivable 0 % 11 %

BASIS OF PRESENTATION (Details

BASIS OF PRESENTATION (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Net loss	$ (74,552)	$ (242,919)
Working capital deficiency	540,184
Related party liabilities	2,299,264
EuroAmerican Investment Corp [Member]
Debt Instrument, Face Amount	300,000
Accrued interest	388,733
Common Stock [Member]
Net loss	$ 236,737

SCHEDULE OF COMMON STOCK NOT IN

SCHEDULE OF COMMON STOCK NOT INCLUDED IN CALCULATION OF DILUTED NET LOSS PER SHARE (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share	4,551,728	6,125,600
Stock Option Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share		660,000
Debentures Convertible into Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share	3,279,676	3,051,106
Preferred Shares Convertible to Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share	1,272,052	1,272,052
Deferred Compensation, Share-Based Payments [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share		1,142,442

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Paycheck Protection Program [Member] | CARES Act [Member]
Short-Term Debt [Line Items]
Proceeds from loan	$ 58,600	$ 58,600

SCHEDULE OF LOSS FROM DISCONTIN

SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Current Assets
Cash	$ 182		$ 380
Total Current Assets	182		380
TOTAL ASSETS	182		380
Current Liabilities
Accounts payable	4		4
Accrued liabilities - Other
Other current liabilities	(620)		(576)
Total Current Liabilities	(616)		$ (572)
Revenue
Cost of Goods Sold
Gross Profit
Operating Expenses:
Selling, general and administrative	751	11,569
Total Operating expenses	751	11,569
Operating Loss	(751)	(11,569)
Other Income (Expense)
Loss on foreign currency exchange	(4)	(603)
Total Other Income (Expense)	(4)	(603)
Loss Before Credit for Income Taxes	(755)	(12,172)
Credit for income taxes
Loss from discontinued operations, net of tax	$ (755)	$ (12,172)

SUMMARY OF NOTES PAYABLE (Detai

SUMMARY OF NOTES PAYABLE (Details) (Parenthetical) - USD ($)	Jul. 07, 2020	Jun. 25, 2018	Mar. 25, 2011	Mar. 25, 2022
Term Note [Member] | EuroAmerican Investment Corp [Member]
Short-Term Debt [Line Items]
Notes issued			$ 300,000
Notes interest rate			16.00%
Conversion due date			Jun. 25, 2011
Term Note [Member] | EuroAmerican Investment Corp [Member] | Extended Maturity [Member]
Short-Term Debt [Line Items]
Conversion due date			Mar. 31, 2023
Economic Injury Disaster Loan Program [Member] | CARES Act [Member]
Short-Term Debt [Line Items]
Notes issued	$ 150,000
Notes interest rate	3.75%
Debt instrument, term	30 years
Debt instrument, periodic payment	$ 731
Peter Zachariou [Member]
Short-Term Debt [Line Items]
Notes issued		$ 30,000
Notes interest rate		10.00%
Fountainhead Capital Management Limited [Member]
Short-Term Debt [Line Items]
Notes issued				$ 370,873
Notes interest rate				10.00%
Debt maturity date description				The Notes will be due between July 2022 and May 2023 or on demand by the Payee.

SUMMARY OF NOTES PAYABLE (Det_2

SUMMARY OF NOTES PAYABLE (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Total Related Party Notes Payable	$ 400,873	$ 320,873
Total Notes Payable	309,057	319,329
Total Long term Notes Payable	148,681	150,000
Economic Injury Disaster Loan Program [Member] | CARES Act [Member]
Short-Term Debt [Line Items]
Total Long term Notes Payable	148,681	150,000
EuroAmerican Investment Corp [Member]
Short-Term Debt [Line Items]
Total Notes Payable	300,000	300,000
Peter Zachariou [Member]
Short-Term Debt [Line Items]
Total Related Party Notes Payable	30,000	30,000
Fountainhead Capital Management Limited [Member]
Short-Term Debt [Line Items]
Total Related Party Notes Payable	370,873	290,873
Current Portion Of Long Term Notes Payable [Member]
Short-Term Debt [Line Items]
Total Notes Payable	1,319
Insurance Policy Finance Agreements [Member]
Short-Term Debt [Line Items]
Total Notes Payable	$ 7,738	$ 19,329

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	Mar. 29, 2022	Jan. 24, 2018	Jan. 31, 2018
Defined Benefit Plan Disclosure [Line Items]
Debt maturity date	Mar. 31, 2023
EuroAmerican Investment Corp [Member]
Defined Benefit Plan Disclosure [Line Items]
Other Notes Payable			$ 300,000
Offering price		$ 0.21
Conversion shares		3,279,676

SCHEDULE OF SUPPLEMENTAL BALANC

SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Lease
Operating Lease ROU Assets	$ 68,053	$ 79,560
Operating Lease ROU Assets	68,053	79,560
Current portion	47,518	46,915
Long-term portion	18,379	30,580
Operating Lease Liabilities	$ 65,897	$ 77,495

SCHEDULE OF BUSINESS SEGMENTS I

SCHEDULE OF BUSINESS SEGMENTS INFORMATION (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Segment Reporting Information [Line Items]
Revenue	$ 313,833	$ 295,749
Gross Profit	280,424	267,272
Total Assets	932,979		$ 935,364
Discontinued Operations [Member]
Segment Reporting Information [Line Items]
Total Assets	182		380
Vycor Medical [Member]
Segment Reporting Information [Line Items]
Revenue	287,356	262,714
Gross Profit	256,337	235,932
Total Assets	910,098		901,930
Nova Vision [Member]
Segment Reporting Information [Line Items]
Revenue	26,477	33,035
Gross Profit	24,087	$ 31,340
Total Assets	$ 22,699		$ 33,054

SUMMARY OF GEOGRAPHIC INFORMATI

SUMMARY OF GEOGRAPHIC INFORMATION (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 313,833	$ 295,749
Gross Profit	280,424	267,272
Total Assets	932,979		$ 935,364
Discontinued Operations [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	182		380
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	310,605	288,780
Gross Profit	277,212	260,371
Total Assets	926,757		928,761
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	3,228	6,969
Gross Profit	3,212	$ 6,901
Total Assets	$ 6,040		$ 6,223

SCHEDULE OF STOCK OPTIONS (Deta

SCHEDULE OF STOCK OPTIONS (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Number of shares Options Outstanding, Beginning Balance		680,000
Weighted average exercise price per share Options, Outstanding, Beginning Balance		$ 0.28
Number of shares Options, Granted
Weighted average exercise price per share Options, Granted
Number of shares Options, Exercised
Weighted average exercise price per share Options, Exercised
Number of shares Options, Cancelled or expired		(680,000)
Weighted average exercise price per share Options, Cancelled or expired		$ 0.28
Number of shares Options, Cancelled or expired		680,000
Number of shares Options Outstanding, Ending Balance
Weighted average exercise price per share Options, Outstanding, Ending balance

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)	Apr. 02, 2021	Jan. 02, 2021	Mar. 31, 2022	Mar. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Weighted average remaining contractual life			0 years
Fountainhead [Member] | Fountainhead Consulting Agreement [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of common stock issued, shares			535,714	535,714
Number of common stock issued, value			$ 45,536	$ 101,430
Non-employee Directors [Member] | Directors Deferred Compensation Plan [Member].
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Issuance of stock related to deferred compensation of directors,shares			0	99,999
Issuance of stock related to deferred compensation of directors, value			$ 0	$ 21,000
Consultant [Member] | Oscar Bronsther [Member] | Consulting Agreement [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of common stock issued, shares		466,794
Consultant [Member] | Ricardo Komotar [Member] | Consulting Agreement [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of common stock issued, shares	101,663

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Non-employee Directors [Member]
Defined Benefit Plan Disclosure [Line Items]
Unrecognized compensation costs	$ 0
Non-employees [Member]
Defined Benefit Plan Disclosure [Line Items]
Share based payment arrangement expense	$ 50,568	$ 122,430

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative)	Oct. 31, 2016USD ($)	Oct. 31, 2016EUR (€)	Jun. 30, 2012USD ($)	Jun. 30, 2012EUR (€)	Mar. 31, 2022USD ($)	Mar. 31, 2022EUR (€)	Mar. 31, 2021USD ($)	Oct. 31, 2016EUR (€)	Jun. 30, 2012EUR (€)
Product Liability Contingency [Line Items]
Payments for rent					$ 20,604		$ 19,477
Trade tax reduced	$ 82,000		$ 82,000					€ 75,000	€ 75,000
Interest expenses	$ 13,200	€ 12,000	$ 13,200	€ 12,000
GERMANY
Product Liability Contingency [Line Items]
Payments for rent					1,815	€ 1,650
Office Space [Member]
Product Liability Contingency [Line Items]
Payments for rent					4,000
Other charges					$ 1,500
Lessee, operating lease, description					The lease terminated September 30, 2020 and was extended for a further three years to August 31, 2023.	The lease terminated September 30, 2020 and was extended for a further three years to August 31, 2023.

CONSULTING AND OTHER AGREEMEN_2

CONSULTING AND OTHER AGREEMENTS (Details Narrative) - USD ($)	Apr. 02, 2021	Mar. 30, 2021	Mar. 31, 2017	Mar. 31, 2022	Mar. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock option cash				$ 50,568	$ 122,430
General Consultancy [Member] | Ricardo J Komotar M D [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of common stock issued for services, shares		304,989
Milestones [Member] | Ricardo J Komotar M D [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of common stock issued, shares	101,663
Number of common stock issued for services, shares		1,219,957
Fountainhead Consulting Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Consulting fee			$ 450,000
Common stock exercise price			$ 0.21
Fountainhead Consulting Agreement [Member] | Fountainhead [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of common stock issued, shares				535,714	535,714
Number of common stock issued, value				$ 45,536	$ 101,430
Fountainhead Consulting Agreement [Member] | Per Month [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Consulting fee			$ 5,000
Fountainhead Consulting Agreement [Member] | January 1, 2021 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock exercise price				$ 0.21
Stock option cash				$ 5,000
Number of common stock issued, shares				535,714
Amended Agreement [Member] | January 1, 2021 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of common stock issued, value				$ 112,500
Consultancy Agreement [Member] | Fountainhead [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of common stock issued, shares				535,714	535,714
Number of common stock issued, value				$ 45,536	$ 101,430

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Related Party Transaction [Line Items]
Accrued dividends	$ 162,185	$ 162,185
Accrued dividends, total	1,784,040	1,459,669
Related party transaction amount	$ 0	$ 0
Fountainhead [Member] | Fountainhead Consulting Agreement [Member]
Related Party Transaction [Line Items]
Stock issued during period, shares, new issues	535,714	535,714
Stock issued during period, value, new issues	$ 45,536	$ 101,430
Fountainhead [Member]
Related Party Transaction [Line Items]
Accrued dividends	113,019	113,019
Accrued dividends, total	1,243,205	1,017,167
Fountainhead [Member] | Unsecured Loan [Member]
Related Party Transaction [Line Items]
Unsecured loan notes issued	$ 80,000	$ 10,000
Unsecured loan notes interest rate	10.00%	10.00%
Unsecured loan maturity description	due on demand or by their one-year anniversary	due on demand or by their one-year anniversary
Peter Zachariou [Member]
Related Party Transaction [Line Items]
Accrued dividends	$ 41,693	$ 41,693
Accrued dividends, total	$ 458,622	$ 375,237
Peter Zachariou [Member] | Series D Preferred Stock [Member]
Related Party Transaction [Line Items]
Equity method investment, ownership percentage	25.70%
Directors [Member] | Fountainhead [Member]
Related Party Transaction [Line Items]
Equity method investment, ownership percentage	61.50%
Directors [Member] | Fountainhead [Member] | Series D Preferred Stock [Member]
Related Party Transaction [Line Items]
Equity method investment, ownership percentage	69.70%
Peter Zachariou [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Equity method investment, ownership percentage	0.16%

SCHEDULE OF CONCENTRATION (Deta

SCHEDULE OF CONCENTRATION (Details) - Customer Concentration Risk [Member] - Integer	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Revenue Benchmark [Member]
Concentration Risk [Line Items]
Number of customers over 10%	0	0
Revenue Benchmark [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	0.00%	0.00%
Accounts Receivable [Member]
Concentration Risk [Line Items]
Number of customers over 10%	0		1
Accounts Receivable [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	0.00%		11.00%

CONCENTRATION (Details Narrativ

CONCENTRATION (Details Narrative) - Purchase [Member] - Customer Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2022
Manufacturer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%
Manufacturer Two [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%
Manufacturer Three [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - shares	Apr. 01, 2022	Mar. 31, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Common stock, shares issued		31,457,415	30,921,701
Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock, shares issued	101,663